Diferencia entre revisiones de «Vitamin K»
(Text replacement - "qd" to "QD") |
(Switch SMW query from broadtable to table format for better layout with TOC) |
||
| (No se muestran 3 ediciones intermedias de 2 usuarios) | |||
| Línea 9: | Línea 9: | ||
==Adult Dosing== | ==Adult Dosing== | ||
===Vitamin K deficiency hypoprothrombinemia=== | ===[[Vitamin K deficiency]] hypoprothrombinemia=== | ||
*2.5-25mg PO QD PRN | *2.5-25mg PO QD PRN | ||
*Max: 25mg/dose | *Max: 25mg/dose | ||
=== | ===[[Anticoagulant]]-induced hypoprothrombinemia=== | ||
*10mg PO x1 | *10mg PO x1 | ||
*Max: 25mg/dose | *Max: 25mg/dose | ||
=== | ===[[Warfarin]] stabilization=== | ||
*100 mcg PO QD-bid | *100 mcg PO QD-bid | ||
| Línea 68: | Línea 68: | ||
==Comments== | ==Comments== | ||
==Indications by Condition== | |||
''The following table is automatically generated from disease/condition pages across WikEM.'' | |||
{{#ask:[[Has DrugName::Vitamin K]] | |||
|?Has Indication=Indication | |||
|?Has Dose=Dose | |||
|?Has Context=Context | |||
|?Has Route=Route | |||
|?Has Population=Population | |||
|format=table | |||
|headers=plain | |||
|mainlabel=- | |||
|sort=Has Indication | |||
|limit=50 | |||
}} | |||
==See Also== | ==See Also== | ||
| Línea 74: | Línea 91: | ||
<references/> | <references/> | ||
[[Category:Pharmacology]] | [[Category:Pharmacology]] | ||
[[Category:FEN]] | |||
Revisión actual - 21:56 20 mar 2026
Disambiguation: See ketamine for street name "vitamin K"
General
- Lasts up to 2 weeks, possibly making anticoagulation post-bleeding risk difficult
- IV form has small risk of anaphylaxis, but risks/benefits must be weighed in serious bleeding
- Type: Vitamin
- Dosage Forms: 100 mcg; 5mg; SC; IM; IV; PO
- Common Trade Names: Generic and Mephyton, K1-1000, Novaplus Vitamin K1
Adult Dosing
Vitamin K deficiency hypoprothrombinemia
- 2.5-25mg PO QD PRN
- Max: 25mg/dose
Anticoagulant-induced hypoprothrombinemia
- 10mg PO x1
- Max: 25mg/dose
Warfarin stabilization
- 100 mcg PO QD-bid
Pediatric Dosing
Neonatal deficiency (hemorrhagic disease of the newborn)
- 1mg SC for avoidance of anaphylaxis (IV), hematoma (IM). FFP for serious cases.
Vitamin K deficiency hypoprothrombinemia
- 2.5-5mg PO QD PRN
anticoagulant induced hypoprothrombinemia
- 0.5-5mg PO/SC/IM/IV x 1
Special Populations
- Pregnancy Rating: C
- Lactation risk: Safe
- Renal Dosing
- Adult: not defined
- Pediatric: not defined
- Hepatic Dosing
- Adult: adjust dose amount
- Pediatric: adjust dose amount
Contraindications
- Allergy to class/drug
- hereditary hypoprothrombinemia
- overanticoagulation due to heparins
- caution in neonates
Adverse Reactions
Serious
- anticoagulant resistance
- hypersensitivity reaction, severe or life-threatening (SC, IM, or IV use)
- anaphylaxis (SC, IM, or IV use)
- hyperbilirubinemia (neonates)
- hemolytic anemia (neonates)
Common
- taste changes (SC, IM, or IV use)
- flushing (SC, IM, or IV use)
- injection site hematoma
- injection site pain
Pharmacology
- Half-life: unknown
- Metabolism: liver, CYP450: unknown
- Excretion: urine, bile
- Mechanism of Action: Used by liver for synthesis of some coagulation factors (II,VII,IX,X,C,S). Timing in the synthesis of these factors impacts reversal of elevated INR (~4 hours: F-VII, ~24 hours: F-II).
Comments
Indications by Condition
The following table is automatically generated from disease/condition pages across WikEM.
| Indication | Dose | Context | Route | Population |
|---|---|---|---|---|
| Anticoagulant reversal for life-threatening bleeds | 10mg IV over 30min | Warfarin reversal with life-threatening bleed (INR >10) | IV | Adult |
| Undifferentiated lower gastrointestinal bleeding | 10mg | Coagulopathy reversal for active GI bleeding | IV | Adult |